Is Eli Lilly Stock a Buy?
While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently showed off his slimmed-down figure in a Santa Claus suit on X calling himself "Ozempic Santa," he wasn't taking Ozempic. Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro.
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock is up about 36% year to date as of this writing and has gained around 506% over the past five years.
Given the stock's strong performance, the natural question becomes whether the stock is still a buy going forward. Let's see if the momentum can continue.
Source Fool.com
